# Adverum Biotechnologies Inc. (ADVM)

Source: https://www.quantisnow.com/company/ADVM
Generated: 2026-11-08T17:54:15.406Z

- Ticker: ADVM
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2014
- Website: adverum.com

## About

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

## Latest ADVM news and filings

- 2025-12-19 21:00 UTC [SEC Form 15-12G filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-adverum-biotechnologies-inc-6323577)
- 2025-12-12 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-adverum-biotechnologies-inc-6313274)
- 2025-12-12 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-adverum-biotechnologies-inc-6313261)
- 2025-12-12 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-adverum-biotechnologies-inc-6313260)
- 2025-12-10 18:52 UTC [SEC Form 4] [CEO, PRESIDENT AND DIRECTOR Fischer Laurent exercised 150,000 shares at a strike of $4.20 and was granted 500,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/ceo-president-and-director-fischer-laurent-exercised-150000-shares-at-6310358)
- 2025-12-10 18:49 UTC [SEC Form 4] [CHIEF OPERATING OFFICER Soparkar Peter was granted 150,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-operating-officer-soparkar-peter-was-granted-150000-units-of-6310354)
- 2025-12-10 18:46 UTC [SEC Form 4] [Chief Medical Officer Ozden Rabia Gurses was granted 85,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-ozden-rabia-gurses-was-granted-85000-units-6310348)
- 2025-12-10 18:44 UTC [SEC Form 4] [CHIEF DEVELOPMENT OFFICER Seyedkazemi Setareh was granted 85,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-development-officer-seyedkazemi-setareh-was-granted-85000-units-of-6310347)
- 2025-12-10 18:41 UTC [SEC Form 4] [CHIEF FINANCIAL OFFICER Rubinstein Linda M was granted 42,000 units of Common Stock - Performance Stock Units and exercised 48,750 shares at a strike of $4.20, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-rubinstein-linda-m-was-granted-42000-units-6310345)
- 2025-12-10 18:38 UTC [SEC Form 4] [SEC Form 4 filed by Director Hong Soo](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-hong-soo-6310340)
- 2025-12-10 18:36 UTC [SEC Form 4] [SEC Form 4 filed by Director Whitcup Scott M](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-whitcup-scott-m-6310338)
- 2025-12-10 18:34 UTC [SEC Form 4] [SEC Form 4 filed by Director Tuckson Reed Vaughn](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-tuckson-reed-vaughn-6310337)
- 2025-12-10 18:31 UTC [SEC Form 4] [Director Svoronos Dawn closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-svoronos-dawn-closing-all-direct-ownership-in-the-company-6310335)
- 2025-12-10 18:29 UTC [SEC Form 4] [Director Scopa James Paul closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-scopa-james-paul-closing-all-direct-ownership-in-the-6310331)
- 2025-12-10 18:27 UTC [SEC Form 4] [SEC Form 4 filed by Director Nicholson, C. David](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-nicholson-c-david-6310326)
- 2025-12-10 18:25 UTC [SEC Form 4] [Director Lupher, Jr. Mark L. closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-lupher-jr-mark-l-closing-all-direct-ownership-in-6310322)
- 2025-12-10 18:22 UTC [SEC Form 4] [Director Machado Patrick closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-machado-patrick-closing-all-direct-ownership-in-the-company-6310318)
- 2025-12-10 18:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Kiss Szilard](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-kiss-szilard-6310312)
- 2025-12-09 23:05 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-adverum-biotechnologies-inc-6309418)
- 2025-12-09 22:31 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-adverum-biotechnologies-inc-6309363)
- 2025-12-09 22:29 UTC [SEC Form 4] [SEC Form 4 filed by Large owner Frazier Life Sciences Public Fund, L.P.](https://www.quantisnow.com/insight/sec-form-4-filed-by-large-owner-frazier-life-sciences-6309341)
- 2025-12-09 21:48 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-adverum-biotechnologies-inc-6309128)
- 2025-12-09 21:47 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-adverum-biotechnologies-inc-6309125)
- 2025-12-09 21:45 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-adverum-biotechnologies-inc-6309120)
- 2025-12-09 21:44 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-adverum-biotechnologies-inc-6309110)
- 2025-12-09 21:43 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-adverum-biotechnologies-inc-6309106)
- 2025-12-09 21:42 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-adverum-biotechnologies-inc-6309101)
- 2025-12-09 21:40 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-adverum-biotechnologies-inc-6309096)
- 2025-12-09 21:39 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-adverum-biotechnologies-inc-6309088)
- 2025-12-09 21:38 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-adverum-biotechnologies-inc-6309084)
- 2025-12-09 21:37 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-adverum-biotechnologies-inc-6309083)
- 2025-12-09 21:36 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-adverum-biotechnologies-inc-6309075)
- 2025-12-09 21:35 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-adverum-biotechnologies-inc-6309064)
- 2025-12-09 21:34 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-adverum-biotechnologies-inc-6309057)
- 2025-12-09 21:33 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-adverum-biotechnologies-inc-6309042)
- 2025-12-09 21:32 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-adverum-biotechnologies-inc-6309019)
- 2025-12-09 21:30 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-adverum-biotechnologies-inc-6309004)
- 2025-12-09 21:29 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-adverum-biotechnologies-inc-6308955)
- 2025-12-09 21:28 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-adverum-biotechnologies-inc-6308946)
- 2025-12-09 21:27 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Adverum Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-adverum-biotechnologies-inc-6308938)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ADVM
- Earnings history: https://www.quantisnow.com/earnings/ADVM
- Dividend history: https://www.quantisnow.com/dividends/ADVM
- Insider transactions: https://www.quantisnow.com/insiders/ADVM
- Options chain: https://www.quantisnow.com/options/ADVM
- SEC 8-K filings only: https://www.quantisnow.com/company/ADVM/8-k
- RSS and alerts for ADVM: https://www.quantisnow.com/docs/rss-feeds.md